

Contents

<i>Foreword</i>	(ix)
<i>Preface</i>	(xi)
<i>Contributors</i>	(xiii)

Chapter 1

Clinical Research – A Clinical Investigator’s Perspective

1.1 Introduction	1
1.2 Scientific and Practical Aspects	2
1.3 Financial Considerations	3

Chapter 2

Medical Device Development, Process and Regulation

2.1 Introduction	5
2.2 Categories of Medical Devices	6
2.3 Evaluation of Medical Devices	6
2.4 Regulatory Process	7

Chapter 3

Pre-Clinical Drug Development

3.1 Introduction	10
3.2 Overview of Drug Discovery and Role of basic Sciences	11
3.3 New Approaches in Drug Discovery	11
3.4 Pharmacological Screening	14

Chapter 4

Phases of Clinical Trials

4.1	Introduction	30
4.2	Phase I	31
4.3	Phase II Studies	37
4.4	Phase III Trials	40
4.5	Phase IV Trials	40

Chapter 5

Phase 0 - Microdosing Studies

5.1	Introduction	42
5.2	Micro-dosing and Exploratory-IND Studies	43
5.3	Characteristics of an Ideal Candidate Drug for Phase 0-Micro-dosing Studies	43
5.4	Goals of Microdosing Studies	44
5.5	Technical Advances	45
5.6	Regulatory Issues	45
5.7	Patient's Perspective	45
5.8	Informed Consent Issues	46
5.9	Single-dose Toxicity Study in Support of Micro-dosing Studies	46
5.10	Advantages of Micro-dosing	46
5.11	Limitations of Micro-dosing	47
5.12	Conclusion	47

Chapter 6

Clinical Research Planning

6.1	Introduction to Clinical Trials	49
6.2	Types of Clinical Trials	51
6.3	The Planning Steps	52

Chapter 7

Clinical Research Design

7.1	Introduction	64
7.2	Elements of Trial Design	65
7.3	Types of Clinical Trial Design	71

Chapter 8

Clinical Research Protocol

8.1	Title Page	82
8.2	Signature Page	82
8.3	Contents Page	82
8.4	List of Abbreviations and Definitions	82
8.5	Summary	83
8.6	Background	83
8.7	Trial Objectives and Purpose	83
8.8	Study Design	83
8.9	Subject Selection	84
8.10	Subject Recruitment	84
8.11	Trial Interventions	84
8.12	Randomisations	85
8.13	Blinding	86
8.14	Data	86
8.15	Statistical Considerations	87
8.16	Compliance and Withdrawal	87
8.17	Interim Analysis and Data Monitoring	88
8.18	Ethical Considerations	89
8.19	Financing and Insurance	89
8.20	Reporting and Publication	89

Chapter 9

Designing Case Report Forms

9.1	Introduction	93
9.2	Uses of CRF	93
9.3	Well-Designed CRF	94
9.4	CRF Design Layout	94
9.5	CRF Field Designs	95
9.6	CRF Verification Before Use	95
9.7	Elements of Trial Design	96
9.8	Electronic Data Entry Forms	98

9.9	Conclusion	99
9.10	Points to Remember	99

Chapter 10

Process of Randomization in Clinical Trials

10.1	Introduction	101
10.2	Advantages of Randomization	102
10.3	Types of Randomization	102
10.4	Techniques of Randomisation	107
10.5	Implementation of Randomization Procedure	110

Chapter 11

Investigational Medicinal Products

11.1	Definition	112
11.2	Manufacturing, Packaging, Labeling, and Coding IMPs	114
11.3	Supply and Handling IMPs	114
11.4	Receipt of IMP, inventory, Storage and Accountability	115
11.5	Randomization code	116
11.6	Principles applicable to comparator product	116
11.7	Blinding Operations	118
11.8	Recall, Return, Shipment and Destruction of IMP	119

Chapter 12

Multi-center Clinical Trials

12.1	Introduction	127
12.2	Advantages and Disadvantages	128
12.3	A Common Protocol	128
12.4	A Coordinating Centre	129
12.5	Comparability of Participating institutions	131
12.6	Committees in a Multi-center Trial	132
12.7	Statistical Issues	133
12.8	Analysis of Results	134
12.9	Multinational Clinical Trials	135

Chapter 13**Good Clinical Research Practice**

13.1	Introduction	138
13.2	Definition of GCP.....	138
13.3	Overview of the Clinical Research Process	139
13.4	Principles of GCP.....	142

Chapter 14**Role and Responsibilities of Sponsor**

14.1	Introduction	159
14.2	Contract Research Organization (CRO).....	160
14.3	The Sponsor and the investigational Products	162
14.4	Sponsor and Record Access	163
14.5	Safety Information	163

Chapter 15**Role and Responsibilities of Principal Investigator**

15.1	Introduction	164
15.2	Competencies and Responsibilities of the Principal Investigator	164
15.3	Qualifications and Availability	167
15.4	Adequate Resources	167
15.5	Informed Consent.....	167
15.6	Investigational Products	168
15.7	Compliance with Protocol	168
15.8	Monitoring and Auditing	169
15.9	Source Data and Other Documentation	169
15.10	Safety Issues and Reporting of Serious Adverse Events	169
15.11	Premature Termination - Breaking the Treatment Code	170
15.12	Progress Reports, Trial Outcome and Final Study Reports	170

Chapter 16

Ethical Consideration in Clinical Research – Special Reference to Developing Countries

16.1	Introduction	174
16.2	Individuals Involved With Ethical Issues	175
16.3	Ethical Issues Related to Protocol Development and Study Design	176
16.4	Issues on Informed Consent	179
16.5	Ethical Issues During Conduct of a Clinical Research	180
16.6	Access to Post Trial Benefits	181
16.7	Need for Developed Countries to Assist Developing Countries in Capacity Building	182

Chapter 17

Informed Consent in Clinical Research

17.1	Introduction	184
17.2	Historical Background	186
17.3	Elements of Informed Consent	186
17.4	Language Used in Consent Forms	187
17.5	Informed Consent Waiver	188
17.6	Revising an Informed Consent	189
17.7	Reconsenting Process	189
17.8	Consent Obtained from Special Groups of Patients	190

Chapter 18

Monitoring in Clinical Trials

18.1	Introduction	203
18.2	Types of Monitoring in Clinical Trials	204
18.3	Key Participant in Monitoring of Clinical Trial	204

Chapter 19

Quality Assurance in Clinical Research

19.1	Monitoring-Details Presented in Chapter on Monitoring	216
19.2	Audit	216

19.3	Inspections	218
19.4	Data Management Metrics	220

Chapter 20

Pharmacovigilance and Drug Safety

20.1	Introduction	228
20.2	Terms Commonly Used in Drug Safety	229
20.3	The Specific Aims of Pharmacovigilance	229
20.4	Definitions	229
20.5	ADR Classification and Evolution	231
20.6	Causality Assessment Scales	234
20.7	Important of Post Marketing Surveillance and ADR Reporting	236
20.8	Characteristics of a Good Adverse Drug Reaction Report	237
20.9	Periodic Safety Update Report (PSUR)	237
20.10	MedDRA or Medical Dictionary for Regulatory Activities	239
20.11	Pharmacovigilance in India	240

Chapter 21

Data and Safety Monitoring Board and Monitoring Plan

21.1	Definition and Purpose	242
21.2	Data Monitoring Committee	243
21.3	Data Safety Monitoring Plan	244

Chapter 22

Standard Operating Procedures

22.1	Introduction	247
22.2	Standard Operating Procedures	248
22.3	SOP Template	251
22.4	Master Formulation Record	252

Chapter 23

Archiving Clinical Research Documents

23.1	Introduction	261
23.2	Stake Holders	262

23.3	What Documents Must Be Archived	263
23.4	How long Should the Documents be Archived	263
23.5	When to Archive Trail Master File (TMF).....	263
23.6	The Archive Building.....	265

Chapter 24

Evidence Based Medicine

24.1	Introduction and Overview	272
24.2	History	273
24.3	Types of EBM	273
24.4	Categories of Evidence	274
24.5	Categories of Recommendations	275
24.6	Statistical Measures	276
24.7	Quality of Clinical Trial Publications	276
24.8	Limitations of Available Evidence	277
24.9	Criticism of Evidence-Based Medicine	277

Chapter 25

Clinical Research Data Management

25.1	Introduction	279
25.2	Protocol	279
25.3	Randomisation	280
25.4	Data Management	281
25.5	Final Study Report	282
25.6	Retention and Securing of Records	283
25.7	Archiving by the Principle Investigator	283
25.8	Archiving by the Sponsor	283

Chapter 26

Clinical Biostatistics

(a) Biostatistics for Clinical Researcher

26(a).1	Introduction	285
26(a).2	Descriptive Statistics	286

26(a).3	Null Hypothesis and Alternative Hypothesis	286
26(a).4	Classifications of Data	288
26(a).5	Test of Hypothesis with the Correct Statistical Tests	289
26(a).6	Summary	290
(b) Terminology Used in Biostatistics		
26(b).1	Introduction to Biostatistics	295
26(b).2	Terminology used in Biostatistics	295
26(b).3	Sampling Unit	298
Glossary		319